Sequana Medical AG Raises CHF 23 Million in a Series C Financing Led by LSP, and Adds an Independent Board Chairman and Vice President of Sales and Marketing

April 28, 2014

ZURICH, April 28, 2014 /PRNewswire/ –

Sequana Medical AG, a private Swiss medical device company with innovative fluid
management technologies, announced today that it has raised CHF 23 million ($26.2 million)
in a Series C preferred share financing round led by LSP (Life Science Partners), and
co-led by NeoMed Management, VI Partners, BioMedInvest, Entrepreneurs Fund and Capricorn
Venture Partners. NeoMed retains its role as the largest investor in Sequana Medical.

Sequana Medical’s alfapump system is a fully implantable battery-powered pump system
that automatically and continually moves excess abdominal fluid, called ascites, from the
abdominal cavity to the bladder, where it is passed naturally from the body. Refractory
ascites is a common complication in patients suffering from liver cirrhosis and certain
cancers and affects over 100,000 patients per year in Europe and the US.

“This financing is a significant milestone for Sequana Medical,” said Noel L. Johnson,
Ph.D., CEO of Sequana Medical. “Funds will be used for global commercial expansion,
initiation of US clinical studies and application of the alfapump technology to new
clinical markets. Fluid overload in ascites and other indications is an area of
significant unmet clinical need and represents more than a $1 billion market opportunity
for Sequana Medical’s proprietary technology. Our clinical and commercial experience to
date has demonstrated that the alfapump system is safe and highly effective.”

“We are excited about the Sequana Medical opportunity. The alfapump system provides
new hope to patients suffering from refractory ascites,” said Rudy Dekeyser, Ph.D.,
Managing Partner at LSP’s Health Economics Fund. “The alfapump is a unique innovation that
both improves the quality of healthcare and reduces the cost and burden of the care
associated with managing refractory ascites.” Rudy Dekeyser will join Sequana Medical’s
Board of Directors.

“We are pleased to be joined by LSP and look forward to working closely with them to
make Sequana Medical’s highly innovative alfapump system available to patients across the
globe. Sequana Medical’s core technology is robust and adaptable to further clinical
applications such as lung and respiratory disease, congestive heart failure and renal
disease,” said Erik Amble, Ph.D., Managing Partner at NeoMed. “I have had the pleasure to
serve as Sequana Medical’s Board Chairman since the Company’s inception.” said Dr. Amble.
“I am pleased to announce that Luzi Andreas von Bidder will take on the role of
Independent Board Chairman. Luzi brings substantial commercial and management experience
to the Sequana Medical Board and we look forward to his guidance as Sequana Medical
becomes a global commercial company.”

Additionally, Sequana Medical is pleased to announce the appointment of Stephen McGill
as Vice President of Sales and Marketing. “Stephen is an experienced global leader with
nearly 30 years of experience in the medical devices industry with specific focus on sales
and marketing execution, supply chain management, geographical expansion and business
development,” said Dr. Johnson. Stephen most recently served as SVP & GM of International
at Angiodynamics. Prior to that, Stephen held key leadership and sales positions with
American Medical Systems, Boston Scientific, Bolton Medical, Stryker and Allergan.

The Company received CE-Mark for the alfapump system in 2011 and its PIONEER study was
published in 2013 in the Journal of Hepatology, Europe’s leading Hepatology journal. A
60-patient multicentre randomised trial will be completed later this year under the
direction of Professor Rajiv Jalan at the Royal Free Hospital, London. The Company is
commercially active in several European countries and is looking to expand its
geographical coverage with the Series C funding.

About Sequana Medical:

Founded in 2006, Sequana Medical AG is a Swiss medical device company backed by NeoMed
Management, VI Partners, Biomed Invest, Capricorn Venture Partners, Entrepreneurs Fund and
Life Science Partners, and is dedicated to improving patient lives through innovative
technologies to manage fluid overload in patients suffering from liver disease, cancer and
congestive heart failure. For more information please visit


About NeoMed Management:

NeoMed Management is an international investment firm registered in Jersey, Channel
Islands, with total capital under management in excess of $300 million that focuses
exclusively on the healthcare products industry. NeoMed invests in all stages of
development from start-up to later stage growth. Since inception in 1997, NeoMed has
successfully invested in more than 40 innovative European and North American companies
with outstanding growth prospects. For more information please visit


About VI Partners:

VI Partners is a Swiss venture capital firm that supports university spin-offs as well
as other promising start-up companies with capital, coaching, consulting and networks.
Venture Incubator was established by McKinsey & Company and the Swiss Federal Institute of
Technology in Zuerich (ETHZ), and started operations in 2001. Currently, VI Partners holds
investments in more than 30 companies. Via the “Venture Incubator” fund VI Partners
invests “Smart Money” to develop promising technology-based ideas for products and
services into successful businesses. It now manages an investment fund of CHF 101 million.
VI Partners investors represent 10 blue-chip enterprises from industry and finance. For
more information please visit http://www.vipartners.ch.

About BioMedPartners:

BioMedPartners is one of the leading European venture capital firms providing private
equity and mezzanine financing to early- and mid-stage healthcare and human life science
companies. The BioMedInvest vehicle targets the entire industry with special focus on
pharmaceuticals, biotechnology, diagnostics and medical technology. Based in Basel,
BioMedPartners has successfully invested in more than 35 human life science companies over
the last ten years, of which a large number have already been listed on the stock exchange
or have been acquired by leading players in the pharmaceutical industry. For more
information please visit http://www.biomedvc.com.

About Capricorn Venture Partners:

Capricorn Venture Partners is an independent European manager of venture capital and
equity funds, investing in innovative European companies with technology as competitive
advantage. It is based in Leuven, Belgium and licensed by the Financial Services and
Markets Authority in Belgium. For more information please visit


About Entrepreneurs Fund:

The Entrepreneurs Fund provides early stage and growth financing alongside active
support to entrepreneurial teams. The Entrepreneurs Fund brings the long term perspective,
experience and global outlook of a family business in its 5th generation. It is their
ambition to create relationships that are valuable and valued, and to actively contribute
more to those relationships. The Entrepreneurs Fund is the venture capital member of the
COFRA Group. For more information please visit http://www.entrepreneursfund.com.

About LSP (Life Science Partners):

LSP (Life Sciences Partners) is one of Europe’s leading investors in the health care
sector. Over more than 25 years, LSP has built elaborate expertise in establishing and
growing health care companies with a positive impact on society. In partnership with
inventors and entrepreneurs LSP contributes to the translation of breakthrough concepts
into products that benefit patients. LSP connects LPs to inventors with a dual goal:
generating an interesting financial return and contributing to the quality of life. LSP’s
Health Economics Fund invests in innovative products contributing to a better and cheaper
health care. For more information please visit the new LSP website:


        Sequana Medical
        Emily Woodward
        Director of Marketing
        Tel: +41-44-403-55-21

SOURCE Sequana Medical AG

Source: PR Newswire

comments powered by Disqus